|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002085,
umls-concept:C0003261,
umls-concept:C0003316,
umls-concept:C0004083,
umls-concept:C0024518,
umls-concept:C0039194,
umls-concept:C0062863,
umls-concept:C0449450,
umls-concept:C0456387,
umls-concept:C0536940,
umls-concept:C0678836,
umls-concept:C1332714,
umls-concept:C1413787,
umls-concept:C1704858,
umls-concept:C2825965
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2001-3-29
|
|
pubmed:abstractText |
NY-ESO-1 is a tumor-specific shared antigen with distinctive immunogenicity. Both CD8(+) T cells and class-switched Ab responses have been detected from patients with cancer. In this study, a CD4(+) T cell line was generated from peripheral blood mononuclear cells of a melanoma patient and was shown to recognize NY-ESO-1 peptides presented by HLA-DP4, a dominant MHC class II allele expressed in 43--70% of Caucasians. The ESO p157--170 peptide containing the core region of DP4-restricted T cell epitope was present in a number of tumor cell lines tested and found to be recognized by both CD4(+) T cells as well as HLA-A2-restricted CD8(+) T cells. Thus, the ESO p157--170 epitope represents a potential candidate for cancer vaccines aimed at generating both CD4(+) and CD8(+) T cell responses. More importantly, 16 of 17 melanoma patients who developed Ab against NY-ESO-1 were found to be HLA-DP4-positive. CD4(+) T cells specific for the NY-ESO-1 epitopes were generated from 5 of 6 melanoma patients with NY-ESO-1 Ab. In contrast, no specific DP4-restricted T cells were generated from two patients without detectable NY-ESO-1 Ab. These results suggested that NY-ESO-1-specific DP4-restricted CD4(+) T cells were closely associated with NY-ESO-1 Ab observed in melanoma patients and might play an important role in providing help for activating B cells for NY-ESO-1-specific Ab production.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10077623,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10204484,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10334988,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10566144,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10587362,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10684854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10725708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-10878395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-1840703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-7675046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-7749984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-7836932,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-7890324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-8022805,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-8170938,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-8642260,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-8642306,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-8976176,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-9050879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-9328128,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-9432985,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-9547346,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-9626360,
http://linkedlifedata.com/resource/pubmed/commentcorrection/11259659-9794842
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/CTAG1B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Epitopes,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DP Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DP beta-Chains,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DPB1 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-DPw4 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class II,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
98
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3964-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:11259659-Alleles,
pubmed-meshheading:11259659-Antibodies,
pubmed-meshheading:11259659-Antibody Formation,
pubmed-meshheading:11259659-Antigens, Neoplasm,
pubmed-meshheading:11259659-CD4-Positive T-Lymphocytes,
pubmed-meshheading:11259659-Cell Line, Transformed,
pubmed-meshheading:11259659-Epitopes,
pubmed-meshheading:11259659-HLA-A2 Antigen,
pubmed-meshheading:11259659-HLA-DP Antigens,
pubmed-meshheading:11259659-HLA-DP beta-Chains,
pubmed-meshheading:11259659-Histocompatibility Antigens Class II,
pubmed-meshheading:11259659-Humans,
pubmed-meshheading:11259659-Membrane Proteins,
pubmed-meshheading:11259659-Proteins
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.
|
|
pubmed:affiliation |
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
|
|
pubmed:publicationType |
Journal Article
|
